AstraZeneca Unit Dodges PTAB Review For $2B Cancer Drug - Law360

AstraZeneca Unit Dodges PTAB Review For $2B Cancer Drug – Law360

Source Node: 2203758
By Dani Kass (August 9, 2023, 9:55 PM EDT) — The Patent Trial and Appeal Board has denied Sandoz Inc.’s challenge to a patent covering Calquence, a cancer drug which had more than $2 billion in sales for AstraZeneca last year….

Time Stamp:

More from Law 360